1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. Massachusetts >
  6. Regeneron Pharmaceuticals Acquires Decibel

M&A Deal Summary

Regeneron Pharmaceuticals Acquires Decibel

On August 9, 2023, Regeneron Pharmaceuticals acquired life science company Decibel for 109M USD

Acquisition Highlights
  • This is Regeneron Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Regeneron Pharmaceuticals’ 2nd largest (disclosed) transaction.
  • This is Regeneron Pharmaceuticals’ 2nd transaction in the United States.
  • This is Regeneron Pharmaceuticals’ 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2023-08-09
Target Decibel
Sector Life Science
Buyer(s) Regeneron Pharmaceuticals
Deal Type Merger
Deal Value 109M USD
Advisor(s) Centerview Partners
Leerink Partners (Financial)
Wilmer Cutler Pickering Hale and Dorr (Legal)

Target

Decibel

Boston, Massachusetts, United States
Decibel is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance. It has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies, and expertise in inner ear biology. The company is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Its pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. Decibel was founded in 2013 and is based in Boston, Massachusetts.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Regeneron Pharmaceuticals

Tarrytown, New York, United States
Category Company
Founded 1988
Sector Life Science
Employees15,106
Revenue 14.2B USD (2024)
DESCRIPTION

Regeneron Pharmaceuticals is a biopharmaceutical company based that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition, and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Merger M&A Deals 1 of 1
State: Massachusetts M&A 2 of 2
Country: United States M&A 2 of 2
Year: 2023 M&A 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-19 Checkmate Pharmaceuticals

Cambridge, Massachusetts, United States

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the activation of innate immunity to treat cancer. Checkmate Pharmaceuticals was formed in 2015 and is based in Cambridge, Massachusetts.

Buy $250M
Mergr

Solution for

Product

Company

Legal